ArticleJournal of clinical medicine2022
Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Preoperative Differential Diagnosis of Benign, Borderline, and Malignant Ovarian Tumors.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Preoperative Pan-Immune-Inflammation Value for the Differential Diagnosis and Prognostic Assessment of Ovarian Tumors: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Diagnostic Value of Simple Ultrasound Features and Inflammatory Markers in Postmenopausal Ovarian Cysts.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Differential diagnosis of benign and malignant ovarian tumors with combined tumor and systemic inflammation-related markers.Journal of Cancer · 2025Article
- Systemic Inflammatory Biomarkers as a Predictive Markers for Ovarian Cancer.International journal of women's health · 2025Article
- Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125.Scientific reports · 2024Article
- Expression of Inflammation Depending on the Stage of Cervical Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors.Journal of ovarian research · 2023Article
- Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR.Journal of ovarian research · 2023Review
- Can the Combination of Magnetic Resonance Imaging, Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predict the Mass Origin in Ovarian Masses?Sisli Etfal Hastanesi tip bulteni · 2023Article
- Development of Nomogram Models Based on Peripheral Blood Score and Clinicopathological Parameters to Predict Preoperative Advanced Stage and Prognosis for Epithelial Ovarian Cancer Patients.Journal of inflammation research · 2023Article
- The Utility of Pre-Treatment Inflammation Markers as Associative Factors to the Adverse Outcomes of Vulvar Cancer: A Study on Staging, Nodal Involvement, and Metastasis Models.Journal of clinical medicine · 2022Article
- The Predictive Role of NLR and PLR in Outcome and Patency of Lower Limb Revascularization in Patients with Femoropopliteal Disease.Journal of clinical medicine · 2022Article
- Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer.Frontiers in oncology · 2022Article
- Systemic inflammation factors as survival prognosis markers in ovarian neoplasm and the relationship with cancer-associated inflammatory mediators-a review.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate whether the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) can be used as supplementary tools to differentiate between benign, borderline, and malignant ovarian tumors. The ratio of patients with benign to borderline to malignant tumors was planned as 3:1:2 considering the incidence of each disease. Consecutive patients were enrolled retrospectively. Preoperative complete blood counts with differentials were investigated, and calculated NLRs and PLRs were analyzed. A total of 630 patients with ovarian tumors were enrolled in this study. The final histopathological results revealed that 318 patients had benign, 108 patients had epithelial borderline, and 204 patients had epithelial malignant ovarian tumors. The NLR and PLR were significantly higher in malignant than in benign or borderline ovarian tumors, and they did not differ significantly between benign and borderline ovarian tumors. The diagnostic cut-off value of NLR for differentiating between benign or borderline and malignant tumors was 2.36, whereas that of PLR for differentiating between benign/borderline and malignancy was 150.02. High preoperative NLR and PLR indicate that the likelihood of epithelial ovarian cancer is higher than that of benign or borderline tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.